Therapeutic potential of targeting IL‐17 and IL‐23 in sepsis
Open accessAbstract
Severe sepsis is a major concern of public health in industrialized countries. It is estimated that in the United States 200,000‐400,000 cases occur annually and resulting in an extensive burden for the health care systems. To date, no FDA‐approved pharmacologic agents for the treatment or prevention of human sepsis are available. The current modalities of therapy in sepsis include the standard arsenal of supportive interventions in critical care medicine and pharmacotherapy, with use of antibiotics and catecholamines. Despite such efforts, the mortality rates of sepsis have remained around 30‐50 %. Extensive scientific studies have utilized animal models of disease and aimed for a better understanding of the pathophysiologic mechanisms during sepsis. Members of the IL‐17 family of cytokines, as well as the functionally related IL‐23, have been identified as new players in the molecular events during sepsis. Strategies for targeting these mediators with neutralizing antibodies during experimental sepsis in rodents have demonstrated efficacy, resulting in improved survival outcomes. Currently, it is not clear whether such findings can be translated to human sepsis. This review highlights the current knowledge on the biology of IL‐17 isoforms and IL‐23 as well as potential applications to clinical medicine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In animal models, reducing neutrophil invasion through IL-17A-blocking antibody has been shown to decrease infarct size and improve neurologic outcome in ischemic stroke, and has been shown to improve survival in endotoxic shock.
“In animal models, reducing neutrophil invasion through IL-17A-blocking antibody has been shown to decreased infarct size and improved neurologic outcome in ischemic stroke [31] and has been shown to improve survival in endotoxic shock [32,33].”
From Oral neutrophils are an independent marker of the systemic inflammatory response after cardiac bypass (2014) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145 · see citing works
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · see citing works
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087 · see citing works
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., & Cua, D. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030896 · Cited by 1,669 · see citing works
Innate IL-17-producing cells: the sentinels of the immune system
Cua, D. J., & Tato, C. M. (2010) · Nature reviews. Immunology · doi:10.1038/nri2800 · Cited by 1,578 · see citing works
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J. J., Garrone, P., Garcia, E., Saeland, S., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2593 · Cited by 1,526 · see citing works
McGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520 · see citing works
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289 · see citing works
Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome
Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., et al. (2008) · Nature · doi:10.1038/nature06764 · Cited by 1,157 · see citing works
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056 · cited 1× · see citing works
“In other forms of chronic mucocutaneous candidiasis disease, presenting with recurrent or persistent infections with Candida albicans, associations with either an autosomal recessive deficiency in the IL-17 receptor A (IL-17RA) or autosomal dominant deficiency in IL-17 F have been described [30].”
BackgroundHuman IL-17: a novel cytokine derived from T cells
Yao, Z., Painter, S. L., Fanslow, W. C., Ulrich, D., Macduff, B. M., Spriggs, M. K., & Armitage, R. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.12.5483 · Cited by 1,021 · see citing works
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A.-M., Painter, S. L., Comeau, M. R., Cohen, J. I., & Spriggs, M. K. (1995) · Immunity · doi:10.1016/1074-7613(95)90070-5 · Cited by 995 · see citing works
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N. M., Guzzo, C. A., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 857 · see citing works
Rouvier, É., Luciani, M., Mattéi, M., Denizot, F., & Golstein, P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.12.5445 · Cited by 776 · see citing works
Shibata, K., Yamada, H., Hara, H., Kishihara, K., & Yoshikai, Y. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4466 · Cited by 481 · see citing works
Wilson, R. H., Whitehead, G. S., Nakano, H., Free, M. E., Kolls, J. K., & Cook, D. N. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0573oc · Cited by 403 · see citing works
Protective effects of C5a blockade in sepsis
Czermak, B. J., Sarma, V. J., Pierson, C. L., Warner, R. L., Huber-Lang, M. S., Bless, N. M., Schmal, H., Friedl, H. P., & Ward, P. A. (1999) · Nature Medicine · doi:10.1038/10512 · Cited by 399 · see citing works
Self-citationFunctional roles for C5a receptors in sepsis
Rittirsch, D., Flierl, M. A., Nadeau, B. A., Day, D. E., Huber-Lang, M. S., Mackay, C. R., Zetoune, F. S., Gerard, N. P., Cianflone, K., Köhl, J., et al. (2008) · Nature Medicine · doi:10.1038/nm1753 · Cited by 386 · see citing works
Self-citationA novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses
Chang, S. H., & Dong, C. (2007) · Cell Research · doi:10.1038/cr.2007.35 · Cited by 280 · see citing works
TLR-2 and IL-17A in Chitin-Induced Macrophage Activation and Acute Inflammation
Silva, C. A. D., Hartl, D., Liu, W., Lee, C. G., & Elias, J. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4279 · Cited by 245 · see citing works
CD4+ T Cells Mediate Abscess Formation in Intra-abdominal Sepsis by an IL-17-Dependent Mechanism
Chung, D. R., Kasper, D. L., Panzo, R. J., Chtinis, T., Grusby, M. J., Sayegh, M. H., & Tzianabos, A. O. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1958 · Cited by 243 · see citing works
Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells
Gu, Y., Yang, J., Ouyang, X., Liu, W., Li, H., Yang, J., Bromberg, J. S., Chen, S., Mayer, L., Unkeless, J. C., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200838331 · Cited by 224 · see citing works
Adverse functions of IL‐17A in experimental sepsis
Flierl, M. A., Rittirsch, D., Gao, H., Hoesel, L. M., Nadeau, B. A., Day, D. E., Zetoune, F. S., Sarma, J. V., Huber-Lang, M. S., Ferrara, J. L. M., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-105221 · Cited by 201 · see citing works
Self-citationThe IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis
Rueda‐Medina, B., Orozco, G., Raya, E., FERNÁNDEZ-SUEIRO, J. L., Mulero, J., Blanco, F. J., Vilches, C., González-Gay, M. Á., & Martin, J. J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080283 · Cited by 165 · see citing works
Eijnden, S. V., Goriely, S., Wit, D. D., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200535467 · Cited by 107 · see citing works
IL‐23 in the Pathogenesis of Rheumatoid Arthritis
Paradowska‐Gorycka, A., Grzybowska-Kowalczyk, A., Wojtecka-Lukasik, E., & Maśliński, S. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02361.x · Cited by 97 · see citing works
Lavoie, P. M., Huang, Q., Jolette, É., Whalen, M., Nuyt, A. M., Audibert, F., Speert, D. P., Lacaze‐Masmonteil, T., Soudeyns, H., & Kollmann, T. R. (2010) · The Journal of Infectious Diseases · doi:10.1086/657143 · Cited by 94 · see citing works
Evidence for anti‐inflammatory effects of C5a on the innate IL‐17A/IL‐23 axis
Bosmann, M., Sarma, J. V., Atefi, G., Zetoune, F. S., & Ward, P. A. (2012) · The FASEB Journal · doi:10.1096/fj.11-199216 · Cited by 67 · see citing works
Self-citationComplement dependency of cardiomyocyte release of mediators during sepsis
Atefi, G., Zetoune, F. S., Herron, T. J., et al. (2011) · The FASEB Journal · doi:10.1096/fj.11-183236 · Cited by 59 · see citing works
Liu, X. K., Clements, J. L., & Gaffen, S. L. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)13236-5 · Cited by 44 · see citing works
O’Dwyer, M. J., Mankan, A. K., White, M., Lawless, M. W., Stordeur, P., O'Connell, B. C., Kelleher, D. P., McManus, R., & Ryan, T. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0968-5 · Cited by 38 · see citing works
Ogiku, M., Kono, H., Hara, M., et al. (2010) · Journal of Surgical Research · doi:10.1016/j.jss.2010.11.901 · Cited by 36 · see citing works
Bosmann, M., Patel, V. R., Russkamp, N. F., Pache, F. C., Zetoune, F. S., Sarma, J. V., & Ward, P. A. (2011) · The FASEB Journal · doi:10.1096/fj.11-191205 · Cited by 32 · see citing works
Self-citationIL-23 neutralization protects mice from Gram-negative endotoxic shock
Belladonna, M. L., Vacca, C., Volpi, C., et al. (2006) · Cytokine · doi:10.1016/j.cyto.2006.04.011 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wilcox, M. E., Charbonney, E., d’Empaire, P. P., Duggal, A., Pinto, R., Javid, A., Dos Santos, C., Rubenfeld, G. D., Sutherland, S., Liles, W. C., et al. (2014) · Journal of Inflammation · doi:10.1186/s12950-014-0032-5 · Cited by 17 · see citing works
“In animal models, reducing neutrophil invasion through IL-17A-blocking antibody has been shown to decreased infarct size and improved neurologic outcome in ischemic stroke [31] and has been shown to improve survival in endotoxic shock [32,33].”
Background
- Authors
- Bosmann, M., & Ward, P. A.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Ward, Peter A
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2012-04-27
- Volume
- 1
- Issue
- 1
- Pages
- 4-4
- ISSN
- 2001-1326 (ISSN-L)
- PMC
- PMC3552565
- OpenAlex
- W2097380570
- Cited by
- 42
- References
- 34
- Citations by year
- 2026: 3 · 2025: 3 · 2023: 5 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 1 · 2013: 3
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (2r01gm061656-09, 5r01gm029507-30)
- National Institute of General Medical Sciences (R01-GM061656, R01-GM029507)
- Topics
- Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- sepsis, IL-17, IL-23, cytokine-targeted therapy, neutralizing antibodies, sepsis pathophysiology, sepsis mortality, animal models of sepsis, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
